Corline Biomedical Q1: Exciting quarters ahead - Redeye

Redeye provides an update following Corline’s Q1 2025 report. Both sales and costs came in slightly below our predictions, but overall, the report was largely in line with our projections. Looking ahead, we emphasise that Corline is entering a critical period, with particular focus on Kardium’s upcoming launch of the CHS-coated Globe system. Following the report, we have made only minor adjustments to our 2025e estimate.

Länk till analysen i sin helhet: https://www.redeye.se/research/1105915/corline-biomedical-q1-exciting-quarters-ahead?utm_source=finwire&utm_medium=RSS